While patients with luminal A cancers may be offered endocrine therapy in addition to surgery and radiation treatment, and patients with HER2-positive cancers may receive additional targeted treatment with monoclonal antibodies, patients with TN cancers currently have no available targeted treatment [4]. This evidence concerns the gene ERBB2 and cancer.